Zacks Investment Research Lowers Nantkwest (NK) to Hold
Zacks Investment Research cut shares of Nantkwest (NASDAQ:NK) from a buy rating to a hold rating in a report released on Wednesday.
According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “
Several other equities research analysts have also commented on NK. BidaskClub lowered Nantkwest from a sell rating to a strong sell rating in a research note on Friday, September 22nd. Raymond James Financial restated a hold rating on shares of Nantkwest in a research report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Nantkwest currently has a consensus rating of Hold and an average price target of $5.25.
Shares of Nantkwest (NK) opened at $4.60 on Wednesday. Nantkwest has a 52 week low of $2.71 and a 52 week high of $8.45. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $363.11, a P/E ratio of -3.62 and a beta of 3.41.
Several hedge funds have recently bought and sold shares of the company. New York State Common Retirement Fund grew its position in shares of Nantkwest by 9.0% in the second quarter. New York State Common Retirement Fund now owns 19,400 shares of the biotechnology company’s stock valued at $147,000 after purchasing an additional 1,599 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Nantkwest by 13.0% in the second quarter. Wells Fargo & Company MN now owns 20,914 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 2,400 shares in the last quarter. Nationwide Fund Advisors grew its position in shares of Nantkwest by 67.6% in the second quarter. Nationwide Fund Advisors now owns 17,302 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 6,977 shares in the last quarter. Voya Investment Management LLC purchased a new stake in shares of Nantkwest in the second quarter valued at approximately $102,000. Finally, Gotham Asset Management LLC purchased a new stake in shares of Nantkwest in the second quarter valued at approximately $104,000. Institutional investors and hedge funds own 19.11% of the company’s stock.
Nantkwest Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with Analyst Ratings Network's FREE daily email newsletter.